CN Stock MarketDetailed Quotes
002589 Realcan Pharmaceutical Group
- 2.88
- -0.09-3.03%
Not Open Jan 2 15:00 CST
4.33BMarket Cap106.67P/E (TTM)
3.00High2.86Low257.68KlotVolume2.96Open2.97Pre Close75.73MTurnover1.89%Turnover Ratio205.71P/E (Static)1.50BShares3.6652wk High0.79P/B3.93BFloat Cap2.0352wk Low3.27Limit Up1.37BShs Float23.91Historical High2.67Limit Down4.71%Amplitude1.89Historical Low0.02Dividend TTM2.94Avg Price153.11KlotAsk0.69%Div YieldTTM100Lot Size99.57KlotBid
Realcan Pharmaceutical Group Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -0.80%6.06B | -1.18%4.03B | -2.62%2.02B | -34.74%8.03B | -43.97%6.11B | -45.97%4.08B | -49.36%2.07B | -41.54%12.31B | -38.21%10.9B | -40.59%7.55B |
| Operating revenue | -0.80%6.06B | -1.18%4.03B | -2.62%2.02B | -34.74%8.03B | -43.97%6.11B | -45.97%4.08B | -49.36%2.07B | -41.54%12.31B | -38.21%10.9B | -40.59%7.55B |
| Other operating revenue | ---- | -22.48%56.3M | ---- | 22.04%57.97M | ---- | 14.59%72.63M | ---- | -67.60%47.5M | ---- | 52.90%63.39M |
| Total operating cost | -3.42%6B | -4.46%4B | -2.82%2.02B | -34.72%8.24B | -42.18%6.21B | -43.07%4.18B | -47.37%2.08B | -38.58%12.62B | -37.34%10.74B | -40.36%7.35B |
| Operating cost | -0.40%5.27B | -0.59%3.53B | 1.27%1.78B | -32.26%7.21B | -41.69%5.29B | -43.09%3.55B | -48.12%1.75B | -38.22%10.64B | -37.37%9.07B | -40.75%6.23B |
| Operating tax surcharges | -28.08%26.8M | -1.69%17.07M | -22.33%7.35M | -12.30%45.72M | -13.73%37.26M | -45.70%17.36M | -48.51%9.46M | -44.37%52.13M | -39.66%43.19M | -35.48%31.98M |
| Operating expense | -26.68%275.36M | -26.57%190.45M | -12.17%89.88M | -49.01%432M | -52.90%375.53M | -51.72%259.37M | -63.37%102.34M | -51.39%847.15M | -42.21%797.27M | -41.89%537.24M |
| Administration expense | -12.43%293.25M | -20.11%175.15M | -3.49%91.62M | -41.67%408.26M | -38.07%334.88M | -36.87%219.25M | -43.56%94.93M | -31.37%699.91M | -32.30%540.79M | -36.08%347.31M |
| Financial expense | -22.04%129.2M | -38.26%83.34M | -53.21%55.66M | -63.37%132.64M | -41.05%165.73M | -30.34%134.98M | 12.25%118.95M | -21.87%362.12M | -30.70%281.14M | -31.94%193.79M |
| -Interest expense (Financial expense) | -32.71%166.71M | -35.51%108.09M | -44.93%67.54M | -25.51%303.7M | -27.57%247.76M | -31.75%167.61M | -20.93%122.64M | -26.46%407.71M | -25.11%342.06M | -20.99%245.58M |
| -Interest Income (Financial expense) | 41.53%-59.34M | 17.26%-44.11M | -23.59%-29.09M | -127.12%-190.71M | 0.68%-101.49M | 39.75%-53.31M | 67.06%-23.54M | 38.41%-83.97M | -5.02%-102.19M | -36.41%-88.49M |
| Research and development | -25.66%7.57M | -12.53%5.48M | 9.03%3.1M | -35.55%14.62M | -1.76%10.18M | -13.02%6.26M | -33.47%2.85M | 96.13%22.68M | 60.43%10.36M | 116.98%7.2M |
| Credit Impairment Loss | -431.23%-42.74M | -175.84%-19.57M | 93.13%31.77M | 76.71%-67.74M | 110.09%12.9M | 169.53%25.8M | 1,043.33%16.45M | -24.30%-290.82M | 9.26%-127.89M | 69.43%-37.11M |
| Asset Impairment Loss | --708.09K | --708.09K | --0 | 84.61%-33.49M | ---- | ---- | --0 | -336.18%-217.64M | -79.56%292.6K | -79.56%292.6K |
| Other net revenue | -103.30%-5.15M | -94.81%8.76M | -26.29%30.86M | 105.67%79.56M | 300.41%156.26M | 676.25%168.89M | 209.27%41.87M | -16,400.70%-1.4B | -28.22%39.02M | -328.63%-29.31M |
| Fair value change income | 104.49%12.46M | ---- | ---- | 46.90%-228.9M | -155.23%-277.42M | -1,936.32%-179.38M | ---32.64M | -560.93%-431.04M | -73.67%-108.69M | 92.16%-8.81M |
| Invest income | -93.03%29.01M | -89.90%32.15M | -90.61%5M | 185.03%408.82M | 59.49%416.51M | 7,175.19%318.35M | 1,838,908.07%53.29M | -518.72%-480.82M | 34.04%261.15M | -97.76%4.38M |
| -Including: Investment income associates | ---- | ---- | ---- | 69.60%-6.07M | ---- | ---- | ---- | -172.50%-19.96M | ---- | ---- |
| Asset deal income | -335.79%-6.47M | -317.12%-5.9M | -322.96%-5.95M | -696.19%-7.92M | -37.35%2.74M | -45.07%2.72M | -62.14%2.67M | -132.54%-995.31K | -23.14%4.38M | -14.58%4.95M |
| Other revenue | 23.02%1.87M | -2.23%1.37M | -98.25%36.63K | -48.04%8.78M | -84.47%1.52M | -79.94%1.4M | -74.52%2.1M | -73.57%16.9M | -82.50%9.79M | -84.11%7M |
| Operating profit | 4.37%53.34M | -33.54%43.09M | -20.00%26.38M | 92.62%-126.64M | -73.93%51.1M | -62.33%64.83M | -78.20%32.98M | -443.90%-1.72B | -64.46%196.03M | -57.05%172.09M |
| Add:Non operating Income | -59.91%1.85M | -67.10%982.76K | -78.02%262.13K | 164.86%2.93M | 29.35%4.62M | 28.57%2.99M | 82.73%1.19M | -89.50%1.11M | -62.15%3.57M | -51.00%2.32M |
| Less:Non operating expense | -64.05%8.07M | 443.57%3.89M | 81.13%2.23M | -58.75%11.72M | 47.96%22.46M | -93.07%714.93K | -79.23%1.23M | -36.33%28.4M | -36.27%15.18M | -31.22%10.31M |
| Total profit | 41.65%47.11M | -40.11%40.19M | -25.89%24.41M | 92.23%-135.42M | -81.97%33.26M | -59.11%67.1M | -77.44%32.94M | -474.96%-1.74B | -65.67%184.42M | -57.97%164.1M |
| Less:Income tax cost | -194.59%-5.14M | -101.43%-365.94K | 97.75%5.84M | -3,331.10%-167.39M | -86.10%5.43M | -2.22%25.52M | -93.77%2.95M | -105.88%-4.88M | -73.58%39.06M | -71.00%26.1M |
| Net profit | 87.73%52.25M | -2.49%40.55M | -38.06%18.57M | 101.84%31.97M | -80.85%27.83M | -69.87%41.59M | -69.58%29.98M | -555.15%-1.74B | -62.67%145.36M | -54.06%138M |
| Net profit from continuing operation | 87.73%52.25M | -2.49%40.55M | -38.06%18.57M | 101.84%31.97M | -80.85%27.83M | -69.87%41.59M | -69.58%29.98M | -555.15%-1.74B | -62.67%145.36M | -54.06%138M |
| Less:Minority Profit | 56.09%13.44M | -12.75%9.53M | -61.44%3.4M | -87.36%11.65M | -89.78%8.61M | -86.18%10.92M | -84.20%8.82M | -63.25%92.17M | -68.07%84.28M | -57.26%79.01M |
| Net profit of parent company owners | 101.90%38.81M | 1.17%31.03M | -28.31%15.17M | 101.11%20.32M | -68.54%19.22M | -48.01%30.67M | -50.49%21.16M | -1,495.74%-1.83B | -51.32%61.08M | -48.95%58.99M |
| Earning per share | ||||||||||
| Basic earning per share | 101.56%0.0258 | 0.98%0.0206 | -28.57%0.01 | 101.09%0.0135 | -68.47%0.0128 | -47.96%0.0204 | -50.00%0.014 | -1,477.78%-1.24 | -51.32%0.0406 | -49.09%0.0392 |
| Diluted earning per share | 101.56%0.0258 | 0.98%0.0206 | -28.57%0.01 | 101.09%0.0135 | -68.47%0.0128 | -47.96%0.0204 | -50.00%0.014 | -1,477.78%-1.24 | -51.32%0.0406 | -49.09%0.0392 |
| Other composite income | ||||||||||
| Total composite income | 87.73%52.25M | -2.49%40.55M | -38.06%18.57M | 101.84%31.97M | -80.85%27.83M | -69.87%41.59M | -69.58%29.98M | -555.15%-1.74B | -62.67%145.36M | -54.06%138M |
| Total composite income of parent company owners | 101.90%38.81M | 1.17%31.03M | -28.31%15.17M | 101.11%20.32M | -68.54%19.22M | -48.01%30.67M | -50.49%21.16M | -1,495.74%-1.83B | -51.32%61.08M | -48.95%58.99M |
| Total composite income of minority owners | 56.09%13.44M | -12.75%9.53M | -61.44%3.4M | -87.36%11.65M | -89.78%8.61M | -86.18%10.92M | -84.20%8.82M | -63.25%92.17M | -68.07%84.28M | -57.26%79.01M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | ZTE Caiguanghua Certified Public Accountants Co., Ltd. (Special General Partnership) | -- | -- | -- | Tianyuanquan Certified Public Accountants Firm (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Heat List
CN
Overall
Symbol
Price
% Chg
No Data
